Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will significantly improve cognitive performance as compared to placebo.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride; Cholinesterase Inhibitors

Criteria

Inclusion Criteria:

• Patient presents with Alzheimer's Disease based on clinical history.

• Patient must have a Mini Mental Status Score between 10 and 26.

• Patient must have a reliable caregiver in frequent or daily contact with the patient.

• Patient must be currently treated with and on a stable dose of a standard Alzheimer's drug treatment for at least 3 months.

Exclusion Criteria:

• Patients who are receiving pharmacologic treatments (other than a cholinesterase inhibitor or memantine) for Alzheimer's Disease.

• Patients who have a history in the past 5 years or any current evidence of major psychiatric illness.

• Patients who have narrow angle glaucoma.

• Patients who are experiencing clinically significant urinary hesitancy or retention as assessed by a physician.